EML4-ALK fusion | GenomeWeb

EML4-ALK fusion

The gene fusion assay maker is the sixth member to join the consortium, which also includes Illumina and several pharmaceutical companies.

Pfizer's Xalkori yielded significantly longer progression-free survival than standard chemotherapy in the Phase III trial of first-line treatment of ALK-positive NSCLC.

Using NanoString's nCounter technology, researchers from Pfizer and Seoul National University have developed an ALK test they hope will be as accurate as the gold standard fluorescence in situ hybridization test for identifying patients who could benefit from Pfizer's Xa

New Releases

Premium

Response Genetics' ResponseDX: Lung

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.